Verastem (VSTM) Receives Coverage Optimism Rating of 0.05

News headlines about Verastem (NASDAQ:VSTM) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Verastem earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.5552597718765 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news headlines that may have impacted Accern’s rankings:

How to Become a New Pot Stock Millionaire

Shares of VSTM stock opened at $2.96 on Monday. Verastem has a fifty-two week low of $1.61 and a fifty-two week high of $5.71. The stock has a market cap of $150.37, a PE ratio of -1.68 and a beta of 2.23. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.13 and a current ratio of 5.13.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.01). sell-side analysts predict that Verastem will post -1.45 EPS for the current year.

Several equities analysts have issued reports on VSTM shares. Cann reiterated a “buy” rating and issued a $15.00 target price (up previously from $6.00) on shares of Verastem in a research note on Sunday, December 10th. Cantor Fitzgerald set a $17.00 target price on Verastem and gave the company a “buy” rating in a research note on Sunday, December 10th. HC Wainwright set a $10.00 target price on Verastem and gave the company a “buy” rating in a research note on Wednesday, December 13th. Raymond James Financial reiterated a “buy” rating on shares of Verastem in a research note on Monday, December 11th. Finally, Zacks Investment Research lowered Verastem from a “hold” rating to a “sell” rating in a research note on Wednesday, February 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $10.14.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3343367/verastem-vstm-receives-coverage-optimism-rating-of-0-05.html.

About Verastem

Verastem, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

Insider Buying and Selling by Quarter for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Chicago Bridge & Iron  Shares Gap Down  on Analyst Downgrade
Chicago Bridge & Iron Shares Gap Down on Analyst Downgrade
Tyler Technologies  Reaches New 12-Month High and Low on Analyst Upgrade
Tyler Technologies Reaches New 12-Month High and Low on Analyst Upgrade
H&R REIT  PT Raised to C$24.50
H&R REIT PT Raised to C$24.50
Tamarack-Valley-Energy  Price Target Increased to C$4.00 by Analysts at Raymond James
Tamarack-Valley-Energy Price Target Increased to C$4.00 by Analysts at Raymond James
Assicurazioni Generali  Given a €15.90 Price Target at Citigroup
Assicurazioni Generali Given a €15.90 Price Target at Citigroup
PrairieSky Royalty  Stock Rating Lowered by TD Securities
PrairieSky Royalty Stock Rating Lowered by TD Securities


© 2006-2018 Ticker Report. Google+.